Nuformix will receive a gross £1.32mln from second tranche of Lanstead funding agreement
The proceeds will be invested in further research and development work on Nuformix’s drug candidates NXP002 and NXP004
Company
Nuformix PLC
LON:NFX
Nuformix PLC is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
51 stories · page 2 of 3
Nuformix says patent application for reformulated AstraZeneca blockbuster has progressed to publication phase
“We believe NXP004 has significant potential and look forward to the granting of the patent in due course,” said Nuformix chairman Alastair Riddell
Nuformix appoints former CEO Dan Gooding as consultant
Gooding instigated the company’s NXP002 programme, which is an inhaled therapy for treating Idiopathic Pulmonary Fibrosis
Nuformix hails progress partner is making with reformulated anti-sickness drug
Oxilio is working with Quotient Sciences, a drug development and manufacturing accelerator
Nuformix raises £1.65mln to fund R&D and business development work
It has inked a subscription agreement with Lannstead Capital
Nuformix aiming to get NXP002 into clinic by end of 2022
The company released strong pre-clinical date earlier this week
Nuformix 'delighted' with preclinical data for lead lung scarring treatment
The company is a specialist in repurposing drugs already on the market for new indications
Nuformix files patent for improved formulation of a £1bn blockbuster drug
NXP004 could provide an advance on an already successful unnamed treatment
Nuformix signs up Oxilio to develop NXP001 oncology asset
Achieving this exclusive global licensing deal for NXP001 in oncology is a major step forward, says chief executive Dr Anne Brindley
Nuformix CEO to step down
The firm said Anne Brindley will continue in her current position for the next six months and has committed to assist the company with an orderly transition
Nuformix says drug pipeline is 'building momentum'
Negotiations are underway about a global license deal for one drug asset to treat the side-effects of chemotherapy
Nuformix secures US patent allowance for NXP002 asset
CEO Anne Brindley said the allowance notice means the patent will proceed to be issued and is an “important endorsement” of the company’s discoveries
Nuformix making progress on three fronts
The company was updating on plans first outlined in March - at the time of its over-subscribed City fundraiser
Nuformix appoints Dr Alastair Riddell as non-exec chair, following reshuffle
"I am delighted to be able to join Nuformix as it develops its portfolio of newly formulated established products for new and important therapeutic indications," said Alastair Riddell
Nuformix eyes big opportunity with new forms of fibrosis and cancer drugs
By developing new forms of safe drugs, the company generates its own intellectual property and may shorten the timeline to market
Nuformix PLC CEO outlines how new funds will help propel the company and its portfolio to the next level
Dr Anne Brindley was speaking after the company said it had conditionally raised just under £1.6mln
Nuformix CEO says £1.6mln of new funding will help take lead asset to 'next value inflexion point'
The proceeds will be put to work developing the portfolio of opportunities, including lead candidate NXP002 for idiopathic pulmonary fibrosis
Nuformix looks to broaden reach of key drug developments
Oxilio took out an option on NXP001 in oncology in September
Nuformix boosts coffers to support ambitious growth plans; looks to target COVID-19 indications for its assets
"The board is positive about the opportunities for the group, in particular, for the development of certain assets for the treatment of Covid-19. Support for these efforts will require additional business development resource”
Nuformix grants six month option over cancer drug candidate
If the option is triggered, Nuformix will receive a “significant upfront payment”, additional development milestones and a royalty on net sales